We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Medpace is a member of the Medical sector. This group includes 957 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Medpace is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MEDP's full-year earnings has moved 10.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, MEDP has returned 59.8% so far this year. Meanwhile, stocks in the Medical group have gained about 1.8% on average. This means that Medpace is outperforming the sector as a whole this year.
Black Diamond (BDTX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 86.5%.
In Black Diamond's case, the consensus EPS estimate for the current year increased 48.4% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Medpace belongs to the Medical Services industry, a group that includes 64 individual companies and currently sits at #155 in the Zacks Industry Rank. This group has lost an average of 0.3% so far this year, so MEDP is performing better in this area.
On the other hand, Black Diamond belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #96. The industry has moved +8.7% year to date.
Medpace and Black Diamond could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Medpace is a member of the Medical sector. This group includes 957 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Medpace is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MEDP's full-year earnings has moved 10.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, MEDP has returned 59.8% so far this year. Meanwhile, stocks in the Medical group have gained about 1.8% on average. This means that Medpace is outperforming the sector as a whole this year.
Black Diamond (BDTX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 86.5%.
In Black Diamond's case, the consensus EPS estimate for the current year increased 48.4% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Medpace belongs to the Medical Services industry, a group that includes 64 individual companies and currently sits at #155 in the Zacks Industry Rank. This group has lost an average of 0.3% so far this year, so MEDP is performing better in this area.
On the other hand, Black Diamond belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #96. The industry has moved +8.7% year to date.
Medpace and Black Diamond could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.